VERU IS ENROLLING PATIENTS
To Evaluate VERU-111 for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Over the last 20 years, a number of viral epidemics have posed a serious global public health risk including Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) in 2002-2003, H1N1 Influenza in 2009, and the Middle East Respiratory Syndrome coronavirus (MERS-CoV) in 2012. Around December 2019, a new viral acute severe respiratory illness emerged in Wuhan, China. In February 2020, the World Health Organization (WHO) announced that the illness COVID-19, caused by a coronavirus named SARS-CoV-2, has been declared a global pandemic with over 4,605,338 cases and 307,280 deaths worldwide and counting (May 15, 2020; Worldometers.info) a critical task
A critical task of COVID-19 is to hijack the host’s internal transportation system, the microtubules of the cytoskeleton.1 Given the spatial distances between the point of virion entry at the plasma membrane to the different locations in the cell for viral replication and release of infectious virions out of the cell, a structural network, the cytoskeleton, is required for efficiency. Viruses take control of their host’s cellular machinery to carry out viral replication, assembly and to exit from the cell to spread infectious virion. The principal cytoskeletal networks involved in viral replication and trafficking (transport) are microtubules and actin which are principally involved in cellular transport. Microtubule networks are dynamic and targeting these networks to disrupt intracellular trafficking to impair virus and host interactions may be an effective way to treat coronavirus infections.